Related Experiment Video
Updated: Aug 30, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer
Kosuke Terazawa1, Toshimitsu Ohashi1, Hirofumi Shibata1
1Department of Otolaryngology - Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Background:
The modified Glasgow prognostic score (mGPS) includes C-reactive protein and serum albumin levels and is a useful prognostic tool for malignant tumors. The immune system affects cancer progression and recurrence and treatment response. We hypothesized that increasing the lymphocyte count improves mGPS, and we created a new prognostic marker termed immune-mGPS (imGPS).
Methods:
This study included 461 patients with head and neck squamous cell carcinoma (HNSCC). The imGPS was calculated as the conventional mGPS with one additional point for a low lymphocyte count (<1250/μL).
Results:
Addition of the lymphocyte count to mGPS significantly increased the area under the time-dependent receiver operating characteristic curve for overall and progression-free survivals. The added predictive abilities of this tool were supported by improvement in both net reclassification and integrated discrimination.
Conclusion:
imGPS is a more accurate predictor of clinical outcome in patients with HNSCC than mGPS.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024